408 Enrichment of tumor cells for cell kinetic analysis in human tumor biopsies using cytokeratin gating

1995 ◽  
Vol 31 ◽  
pp. S89
Author(s):  
I. Hofland ◽  
K. Haustermans ◽  
A.C. Begg
1996 ◽  
Vol 41 (3) ◽  
pp. 237-248 ◽  
Author(s):  
K. Haustermans ◽  
I. Hofland ◽  
M. Ramaekers ◽  
D. Ivanyi ◽  
A.J.M. Balm ◽  
...  

1987 ◽  
Vol 17 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Shigehiro Kikuyama ◽  
Tetsuro Kubota ◽  
Masahiko Watanabe ◽  
Yoh Isobe ◽  
Takashi Fukutomi ◽  
...  

1996 ◽  
Vol 40 ◽  
pp. S138
Author(s):  
K. Haustermans ◽  
I. Hofland ◽  
A.C. Begg

1975 ◽  
Vol 150 (3) ◽  
pp. 597-601 ◽  
Author(s):  
G. M. Mavligit ◽  
P. B. Barsales ◽  
J. U. Gutterman ◽  
B. MacKay ◽  
E. M. Hersh

1983 ◽  
Vol 50 (03) ◽  
pp. 726-730 ◽  
Author(s):  
Hamid Al-Mondhiry ◽  
Virginia McGarvey ◽  
Kim Leitzel

SummaryThis paper reports studies on the interaction between human platelets, the plasma coagulation system, and two human tumor cell lines grown in tissue culture: Melanoma and breast adenocarcinoma. The interaction was monitored through the use of 125I- labelled fibrinogen, which measures both thrombin activity generated by cell-plasma interaction and fibrin/fibrinogen binding to platelets and tumor cells. Each tumor cell line activates both the platelets and the coagulation system simultaneously resulting in the generation of thrombin or thrombin-like activity. The melanoma cells activate the coagulation system through “the extrinsic pathway” with a tissue factor-like effect on factor VII, but the breast tumor seems to activate factor X directly. Both tumor cell lines activate platelets to “make available” a platelet- derived procoagulant material necessary for the conversion of prothrombin to thrombin. The tumor-derived procoagulant activity and the platelet aggregating potential of cells do not seem to be inter-related, and they are not specific to malignant cells.


2019 ◽  
Vol 65 (5) ◽  
pp. 760-765
Author(s):  
Margarita Tyndyk ◽  
Irina Popovich ◽  
A. Malek ◽  
R. Samsonov ◽  
N. Germanov ◽  
...  

The paper presents the results of the research on the antitumor activity of a new drug - atomic clusters of silver (ACS), the colloidal solution of nanostructured silver bisilicate Ag6Si2O7 with particles size of 1-2 nm in deionized water. In vitro studies to evaluate the effect of various ACS concentrations in human tumor cells cultures (breast cancer, colon carcinoma and prostate cancer) were conducted. The highest antitumor activity of ACS was observed in dilutions from 2.7 mg/l to 5.1 mg/l, resulting in the death of tumor cells in all studied cell cultures. In vivo experiments on transplanted Ehrlich carcinoma model in mice consuming 0.75 mg/kg ACS with drinking water revealed significant inhibition of tumor growth since the 14th day of experiment (maximally by 52% on the 28th day, p < 0.05) in comparison with control. Subcutaneous injections of 2.5 mg/kg ACS inhibited Ehrlich's tumor growth on the 7th and 10th days of the experiment (p < 0.05) as compared to control.


Sign in / Sign up

Export Citation Format

Share Document